BMS, Lundbeck execs jump ship

Two C-level execs abruptly exited their respective buildings this week. Danish drug maker Lundbeck lost its CEO Claus Braestrup yesterday when he announced he would resign immediately. The 63-year-old had said he planned to leave after announcing 2007 results, but officials didn't expect him to take a flyer. "It is regrettable that Claus Braestrup has decided to resign from his position sooner than we had expected," a board member said. No kidding: The company just posted its best financial performance ever.

Meanwhile, Bristol-Myers Squibb's executive VP and CFO Andrew Bonfield will leave the company "to seek new career opportunities;" he'll be replaced by Jean-Marc Huet, CFO at Amsterdam's Royal Numico, where he engineered some acquisitions. Bonfield will stick around to help Huet make the transition. In a news release, CEO Jim Cornelius (photo) stated that Bonfield ID'd Huet as a potential successor last year. A company spokeswoman told Pharmalot that Bonfield's departure is "completely unrelated" to a $275 million charge on subprime securities losses, though the corporate treasurer and controller was a casualty. "He's been talking to Jim since 2007 about his role and career plans," the spokeswoman said.

- see Lundbeck's press release
- read the release from Bristol-Myers
- check out Pharmalot's coverage here and here

Suggested Articles

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.

With federal prosecutors laying waste to Insys' executive team, one big domino was still left to fall: Founder and former CEO John Kapoor.

Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.